Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · IEX Real-Time Price · USD
2.440
+0.300 (14.02%)
Apr 5, 2024, 3:59 PM EDT - Market closed
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey A. Meckler |
Contact Details
Address: 3 Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | (646) 427-2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J105 |
| ISIN Number | US45339J1051 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey A. Meckler | Chief Executive Officer and Director |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
| Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 7, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 424B5 | Filing |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |